59886-85-0

Basic information

• Product Name: 4-Chloro-2-(hydroxymethyl)-3-methylpyridine
• Synonyms: 4-Chloro-2-(hydroxymethyl)-3-methylpyridine;4-Chloro-3-Methyl-2-pyridineMethanol;(4-Chloro-3-methylpyridin-2-yl)methanol
• CAS NO: 59886-85-0
• Molecular Formula: C₇H₈ClNO
• Molecular Weight: 157.59752
• Product Categories: Aromatics;Heterocycles;Intermediates;Miscellaneous Reagents
• Mol File: 59886-85-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 46-47 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 262.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.263±0.06 g/cm3(Predicted)
• Solubility: Chloroform, Dichloromethane, Methanol
• PKA: 13.15±0.10(Predicted)
• CAS DataBase Reference: 4-Chloro-2-(hydroxymethyl)-3-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-(hydroxymethyl)-3-methylpyridine(59886-85-0)
• EPA Substance Registry System: 4-Chloro-2-(hydroxymethyl)-3-methylpyridine(59886-85-0)

Safety Data

• Hazardous Substances Data: 59886-85-0(Hazardous Substances Data)

Usage

Chemical Properties

Pale Orange Solid

Uses

4-Chloro-2-(hydroxymethyl)-3-methylpyridine can act as intermediate used in the preparation of potential antineoplastic agents

Upstream product

• 59886-90-7 4-chloro-2,3-dimethylpyridine-N-oxide 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 59886-84-9 (4-chloro-3-methylpyridin-2-yl)methyl acetate 

Downstream Products

• 152402-97-6 2-chloromethyl-4-chloro-3-methylpyridine hydrochloride 
• 103312-62-5 2-[(4-chloro-3-methylpyridin-2-yl)methylsulfanyl]-1H-benzoimidazole 
• 168167-42-8 2-[(RS)-[(4-chloro-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole 

Relevant articles and documents

Immune checkpoint small-molecule inhibitor as well as preparation method and application thereof

The invention provides a PD-1/PD-L1 interaction inhibitor as well as a preparation method, pharmaceutical composition and application thereof. Specifically, the invention provides a compound with a structure as shown in a formula (I), and definition of each functional group is described in the specification. The compound and a composition containing the compound can be used for treating and/or preventing diseases related to PD-1/PD-L1 signaling pathways, such as cancers, infectious diseases and autoimmune diseases.

Identification and synthesis of potential impurities of rabeprazole sodium

Rabeprazole sodium (1, Achiphex) is a gastric proton pump inhibitor. It causes dose-dependent inhibition of acid secretion and is useful as an anti-ulcer agent. In the process for the preparation of 1, two potential unknown impurities were identified in HPLC at levels ranging from 0.05-0.8%. Based on mass spectral data vide LC-MS, the two impurities were characterized as 2-{[(4-chloro-3-methyl-2-pyridinyl) methyl] sulfinyl}-1H-bezimidazole (2, chloro analogue of rabeprazole) and 2-[{(4-methoxy-3-methyl-2-pyridinyl)methyl} sulfinyl]-1H-benzimidazole (3, methoxy analogue of rabeprazole). The structures were unambiguously established by independently synthesizing them and co-injecting in HPLC. To our knowledge, the compounds 2 and 3 have not been reported as process impurities elsewhere.

Potential antitumor agents. 14. 4 Substituted 2 formylpyridine thiosemicarbazones

A series of 4 substituted 2 formylpyridine thiosemicarbazones has been synthesized which contain a tertiary N at the 4 position. These materials were obtained by reacting 4 nitro 2 picoline N oxide, either directly or after conversion to the corresponding 4 chloro derivative, with a variety of secondary amines. Rearrangement of the 4 substituted 2 picoline N oxides with Ac2O yielded respective methyl acetates, which upon acid hydrolysis, MnO2 oxidation, and reaction with thiosemicarbazide resulted in the desired compounds. An alternate procedure which consisted of reacting 4 chloro 2 formylpyridine ethylene acetal with various amines, followed by hydrolysis and reaction with thiosemicarbazide, was also employed. Introduction of an alkyl group at the 3 position of the pyridine ring of 4 morpholino 2 formylpyridine thiosemicarbazone was achieved by utilizing 2,3 dimethyl 4 nitropyridine N oxide; this material was converted to the corresponding 4 chloro derivative which was then subjected to nucleophilic substitution. 4 Morpholino 2 formylpyridine thiosemicarbazone was the most active antineoplastic agent of this series in mice bearing Sarcoma 180 ascites cells and was significantly superior to 5 hydroxy 2 formylpyridine thiosemicarbazone in this test system.